Ratings Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-7.89%	-28.57%

Jul. 01	Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine	MT
Jul. 01	New semester, new state of mind

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
VALNEVA SE PREF.	-28.57%	521M	-
MODERNA, INC.	+22.10%	46.55B	B-
LONZA GROUP AG	+46.45%	41.84B	A
IQVIA HOLDINGS INC.	-3.12%	40.84B	B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B	B
CELLTRION, INC.	-6.30%	28.27B	C
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B	B-
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B	B+
MEDPACE HOLDINGS, INC.	+44.52%	13.69B	C+
BIO-TECHNE CORPORATION	+0.19%	12.18B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes